GAS5 and lip and oral cavity carcinoma: In HCC [70], oral cancer [25], and uterine cervical cancer [71], the promoter variant rs145204276 may impact GAS5’s tumor suppressive effect; nevertheless, its tumor suppressive activity has been described in osteosarcoma, where allele deletion was associated with enhanced GAS5 expression and smaller tumors [27].